Table 4_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

Table 3_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

Table 2_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

Data Sheet 1_Cerebrospinal fluid and serum cytokine profiles in severe viral encephalitis with implications for refractory status epilepticus: a retrospective observational study.d... by Peipei Huang (3623933)

“…Notably, 18.9% of these patients developed RSE, with a mortality rate of 20%. During the early stage of SVE, CSF interleukin (IL)-6 and IL-8 levels were significantly higher, declining over time and affecting the prognosis. …”

Table 5_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

Table 6_Global, regional and national burden of traumatic amputations from 1990 to 2021: a systematic analysis of the Global Burden of Disease study 2021.docx by Baixing Wei (21461966)

Data Sheet 1_Efficacy and safety of SGLT2 inhibitors in acute heart failure: a systematic review and meta-analysis of randomized controlled trials.docx by Ali Ibrahim Rahil (21225326)

“…The meta-analysis was performed using Revman, where the risk ratio (RR) and mean difference (MD) with a 95% confidence interval (CI) were used for dichotomous and continuous variablesrespectively.…”

Data Sheet 1_Immediate versus staged complete revascularization in patients with acute coronary syndrome and multivessel disease: a meta-analysis of randomized controlled trials.pd... by Lin He (102807)

“…</p>Results<p>In total, 11 randomized studies involving 5,666 patients met the inclusion criteria. At a mean follow-up of 16 months, immediate complete revascularization significantly decreased the incidence of MACE compared with staged complete revascularization [RR: 0.76, 95% confidence interval (CI): 0.66–0.89, P = 0.0004]. …”

Table 2_Prognostic value of platelet to lymphocyte ratio (PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.docx by Ziqian Zhao (9518348)

“…</p>Conclusions<p>Elevated PLR is significantly correlated with poorer clinical outcomes in BC patients undergoing NACT, suggesting its potential as a predictive biomarker for treatment efficacy. …”

Table 1_A real-world study of polyenyl phosphatidylcholine in the management of patients with metabolic dysfunction-associated fatty liver disease in China clinical practice.docx by Yi Pan (68170)

Table 1_Prognostic value of platelet to lymphocyte ratio (PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis.docx by Ziqian Zhao (9518348)

“…</p>Conclusions<p>Elevated PLR is significantly correlated with poorer clinical outcomes in BC patients undergoing NACT, suggesting its potential as a predictive biomarker for treatment efficacy. …”

Table 1_Combined oven/freeze drying as a cost and energy-efficient drying method for preserving quality attributes and volatile compounds of carrot slices.docx by Zobabalo Progress Mina (20532509)

“…Combined drying represents a novel approach that addresses the shortcomings of conventional methods by balancing energy consumption, cost, and product quality.…”

Table 3_Effects of extracorporeal carbon dioxide removal in facilitating ultra-protective ventilation strategies for patients with acute respiratory distress syndrome: a systematic... by Weifeng Zhen (12969341)

“…ECCO₂R significantly reduced driving pressure (weighted mean difference [WMD]: −3.70 cmH₂O; 95% CI: −4.05 to −3.34; P < 0.001), plateau pressure (WMD: −3.26 cmH₂O; 95% CI: −3.70 to −2.82; P < 0.001), and tidal volume (WMD: −1.68 mL/kg; 95% CI: −1.81 to −1.55; P < 0.001) at 24 h, while it increased positive end-expiratory pressure (WMD: 0.64 cmH₂O; 95% CI: 0.44 to 0.85; P < 0.001). …”

Table 1_Effects of extracorporeal carbon dioxide removal in facilitating ultra-protective ventilation strategies for patients with acute respiratory distress syndrome: a systematic... by Weifeng Zhen (12969341)

“…ECCO₂R significantly reduced driving pressure (weighted mean difference [WMD]: −3.70 cmH₂O; 95% CI: −4.05 to −3.34; P < 0.001), plateau pressure (WMD: −3.26 cmH₂O; 95% CI: −3.70 to −2.82; P < 0.001), and tidal volume (WMD: −1.68 mL/kg; 95% CI: −1.81 to −1.55; P < 0.001) at 24 h, while it increased positive end-expiratory pressure (WMD: 0.64 cmH₂O; 95% CI: 0.44 to 0.85; P < 0.001). …”

Table 2_Effects of extracorporeal carbon dioxide removal in facilitating ultra-protective ventilation strategies for patients with acute respiratory distress syndrome: a systematic... by Weifeng Zhen (12969341)

“…ECCO₂R significantly reduced driving pressure (weighted mean difference [WMD]: −3.70 cmH₂O; 95% CI: −4.05 to −3.34; P < 0.001), plateau pressure (WMD: −3.26 cmH₂O; 95% CI: −3.70 to −2.82; P < 0.001), and tidal volume (WMD: −1.68 mL/kg; 95% CI: −1.81 to −1.55; P < 0.001) at 24 h, while it increased positive end-expiratory pressure (WMD: 0.64 cmH₂O; 95% CI: 0.44 to 0.85; P < 0.001). …”

Table 4_Effects of extracorporeal carbon dioxide removal in facilitating ultra-protective ventilation strategies for patients with acute respiratory distress syndrome: a systematic... by Weifeng Zhen (12969341)

“…ECCO₂R significantly reduced driving pressure (weighted mean difference [WMD]: −3.70 cmH₂O; 95% CI: −4.05 to −3.34; P < 0.001), plateau pressure (WMD: −3.26 cmH₂O; 95% CI: −3.70 to −2.82; P < 0.001), and tidal volume (WMD: −1.68 mL/kg; 95% CI: −1.81 to −1.55; P < 0.001) at 24 h, while it increased positive end-expiratory pressure (WMD: 0.64 cmH₂O; 95% CI: 0.44 to 0.85; P < 0.001). …”

Table 5_Effects of extracorporeal carbon dioxide removal in facilitating ultra-protective ventilation strategies for patients with acute respiratory distress syndrome: a systematic... by Weifeng Zhen (12969341)

“…ECCO₂R significantly reduced driving pressure (weighted mean difference [WMD]: −3.70 cmH₂O; 95% CI: −4.05 to −3.34; P < 0.001), plateau pressure (WMD: −3.26 cmH₂O; 95% CI: −3.70 to −2.82; P < 0.001), and tidal volume (WMD: −1.68 mL/kg; 95% CI: −1.81 to −1.55; P < 0.001) at 24 h, while it increased positive end-expiratory pressure (WMD: 0.64 cmH₂O; 95% CI: 0.44 to 0.85; P < 0.001). …”

DataSheet1_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

“…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”

DataSheet2_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

“…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”

DataSheet3_Risk of bone fracture by using dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in patients wit... by Mohamed E. A. Mostafa (19834779)

“…The risk of fracture was identified with the follow-up duration for each class. We found a significant decrease in the fracture risk by about 87% associated with patients who used SGLT2 inhibitors in combination with other glucose-lowering medications, followed by SGLT2 inhibitors alone by about 67%, then GLP-1 receptor agonists by about 60%, and at last DPP-4 inhibitors by about 55%.…”